Open AccessImpact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention
Author(s) -
Nihar R. Desai,
William J. Canestaro,
Pavlo Kyrychenko,
Donald Chaplin,
Lori A. Martell,
Troyen A. Brennan,
Olga S. Matlin,
Niteesh K. Choudhry
Publication year - 2013
Publication title -
circulation cardiovascular quality and outcomes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.692
H-Index - 87
eISSN - 1941-7705
pISSN - 1941-7713
DOI - 10.1161/circoutcomes.113.000321
Subject(s) - clopidogrel , prasugrel , medicine , cyp2c19 , percutaneous coronary intervention , acute coronary syndrome , pharmacogenomics , cardiology , pharmacology , aspirin , myocardial infarction , cytochrome p450 , metabolism
Patients treated with clopidogrel who have ≥1 loss of function alleles for CYP2C19 have an increased risk for adverse cardiovascular events. In 2010, the US Food and Drug Administration issued a boxed warning cautioning against the use of clopidogrel in such patients. We sought to assess the impact of CYP2C19 genetic testing on prescribing patterns for antiplatelet therapy among patients with acute coronary syndrome or percutaneous coronary intervention.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom